Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics
Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.
Medical Devices & Diagnostics
Pharma & Biotech
Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.
Pharma & Biotech
Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
Discover how Sapu Nano’s Deciparticle platform could reshape oncology drug delivery and expand intravenous everolimus development.
Medical Devices & Diagnostics
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Medical Devices & Diagnostics
How Agendia’s breast cancer assays are testing the limits of race-based clinical assumptions
Race matters in care access, but tumor biology may drive response. Agendia’s FLEX data sharpen the breast cancer equity debate.
Medical Devices & Diagnostics
Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
Artera has won CE marking for its AI prostate and breast cancer assays. Read what this means for oncology diagnostics, adoption, and global expansion.
Pharma & Biotech
From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Medical Devices & Diagnostics
Can Hologic’s breast imaging AI close one of mammography’s most stubborn detection gaps?
Hologic’s latest breast imaging AI data suggests stronger detection of hard-to-find cancers. Read what it could mean for screening adoption.
Pharma & Biotech
Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
Discover how AKTX-101 could redefine TROP2 ADC resistance strategies in oncology. Read the full analysis now.
Pharma & Biotech
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.